Patents by Inventor David Anthony Rider

David Anthony Rider has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Nucleic acids for inhibiting expression of LPA in a cell
    Patent number: 11499153
    Abstract: The present invention relates to products and compositions and their uses. In particular the invention relates to nucleic acid products that interfere with the LPA gene expression or inhibit its expression, preferably for use as treatment, prevention or reduction of risk of suffering cardiovascular disease such as coronary heart disease or aortic stenosis or stroke or any other disorder, pathology or syndrome linked to elevated levels of Lp(a) particles.
    Type: Grant
    Filed: December 22, 2021
    Date of Patent: November 15, 2022
    Assignee: SILENCE THERAPEUTICS GMBH
    Inventors: David Anthony Rider, Lucas Bethge, Christian Frauendorf, Adrien Weingärtner, Judith Hauptmann, Sibylle Dames, Steffen Schubert, Stephan Tenbaum
  • NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF LPA IN A CELL
    Publication number: 20220290144
    Abstract: The present invention relates to products and compositions and their uses. In particular the invention relates to nucleic acid products that interfere with the LPA gene expression or inhibit its expression for use as treatment, prevention or reduction of risk of suffering cardiovascular disease such as coronary heart disease or aortic stenosis or stroke or any other disorder, pathology or syndrome linked to elevated of Lp(a)-containing particles.
    Type: Application
    Filed: March 17, 2022
    Publication date: September 15, 2022
    Inventors: Sibylle Dames, Steffen Schubert, Stephan Tenbaum, Christian Frauendorf, Lucas Bethge, Judith Hauptmann, Adrien Weingartner, David Anthony Rider
  • NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF LPA IN A CELL
    Publication number: 20220170016
    Abstract: The present invention relates to products and compositions and their uses. In particular the invention relates to nucleic acid products that interfere with the LPA gene expression or inhibit its expression, preferably for use as treatment, prevention or reduction of risk of suffering cardiovascular disease such as coronary heart disease or aortic stenosis or stroke or any other disorder, pathology or syndrome linked to elevated levels of Lp(a) particles.
    Type: Application
    Filed: December 22, 2021
    Publication date: June 2, 2022
    Inventors: David Anthony Rider, Lucas Bethge, Christian Frauendorf, Adrien Weingaertner, Judith Hauptmann, Sibylle Dames, Steffen Schubert, Stephan Tenbaum
  • Nucleic acids for inhibiting expression of LPA in a cell
    Patent number: 11319537
    Abstract: The present invention relates to products and compositions and their uses. In particular the invention relates to nucleic acid products that interfere with the LPA gene expression or inhibit its expression for use as treatment, prevention or reduction of risk of suffering cardiovascular disease such as coronary heart disease or aortic stenosis or stroke or any other disorder, pathology or syndrome linked to elevated of Lp(a)-containing particles.
    Type: Grant
    Filed: November 13, 2018
    Date of Patent: May 3, 2022
    Assignee: SILENCE THERAPEUTICS GMBH
    Inventors: Sibylle Dames, Steffen Schubert, Stephan Tenbaum, Christian Frauendorf, Lucas Bethge, Judith Hauptmann, Adrien Weingärtner, David Anthony Rider
  • NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF LPA IN A CELL
    Publication number: 20220002722
    Abstract: The present invention relates to products and compositions and their uses. In particular the invention relates to nucleic acid products that interfere with the LPA gene expression or inhibit its expression, preferably for use as treatment, prevention or reduction of risk of suffering cardiovascular disease such as coronary heart disease or aortic stenosis or stroke or any other disorder, pathology or syndrome linked to elevated levels of Lp(a) particles.
    Type: Application
    Filed: November 13, 2019
    Publication date: January 6, 2022
    Inventors: David Anthony Rider, Lucas Bethge, Christian Frauendorf, Adrien Weingaertner, Judith Flauptmann, Sibylle Dames, Steffen Schubert, Stephan Tenbaum
  • NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF LPA IN A CELL
    Publication number: 20210123048
    Abstract: The present invention relates to products and compositions and their uses. In particular the invention relates to nucleic acid products that interfere with the LPA gene expression or inhibit its expression for use as treatment, prevention or reduction of risk of suffering cardiovascular disease such as coronary heart disease or aortic stenosis or stroke or any other disorder, pathology or syndrome linked to elevated of Lp(a)-containing particles.
    Type: Application
    Filed: November 13, 2018
    Publication date: April 29, 2021
    Inventors: Sibylle Dames, Steffen Schubert, Stephan Tenbaum, Christian Frauendorf, Lucas Bethge, Judith Hauptmann, Adrien Weingärtner, David Anthony Rider